Semaglutide Generics: What the UK Picture Actually Looks Like

Why can't you buy a generic version of semaglutide in the UK today?

A medicine goes generic when its originator's patent lapses and other manufacturers can submit their own regulatory dossiers to prove bioequivalence. Novo Nordisk holds multiple overlapping patents on semaglutide, covering the molecule itself, the formulation, the delivery device and manufacturing processes. In the UK, the MHRA licenses medicines on the basis of safety, quality and efficacy data; a generic applicant must demonstrate that their product matches the reference medicine in all clinically relevant respects before a licence is granted.

Those patents have not yet expired in the UK. Some legal challenges have been mounted in the US, where the patent landscape differs, but US rulings do not bind the MHRA or UK courts. The practical upshot is that anyone buying an "unbranded semaglutide" product online is not buying a licensed generic, and you can read more about what semaglutide generic products actually are and why they differ from licensed medicines on our dedicated page. They are buying something that has bypassed the entire regulatory process. The MHRA has warned explicitly about the risks of unlicensed weight-loss products sold via social media and websites, products with no verified concentration, no sterility guarantee and no oversight. You can find out more about when semaglutide patents are expected to expire in our dedicated page on the topic, which tracks the current legal picture carefully.

The NHS medicines page for semaglutide is the clearest starting point if you want to understand what the licensed product is, what it contains, and what clinical monitoring it requires.

Is "compounded semaglutide" the same as a generic?

No. Compounding and generic manufacture are entirely different things. A licensed generic goes through full MHRA review and is produced to GMP (Good Manufacturing Practice) standards. Compounded products are mixed in a pharmacy to serve an individual patient where no licensed product is available or suitable, a narrow clinical exception, not a route to a cheaper version of a branded medicine.

In the US, compounding pharmacies produced large volumes of semaglutide during shortage periods, which attracted significant FDA scrutiny. UK regulations are stricter: licensed medicines in adequate supply cannot lawfully be routinely compounded as a substitute. Any clinic or website offering "compounded semaglutide" in the UK as a standard treatment is operating outside the regulatory framework. This is worth stating plainly, because some of those products are reaching UK consumers through social media advertising.

If you are wondering whether the generic name of the product matters for how it is prescribed or priced, our page on the generic name of Wegovy explains the distinction between brand and active ingredient in straightforward terms. For a broader look at what semaglutide is and how it works as a GLP-1 receptor agonist, that page covers the mechanism, the licensed indications and the trial evidence in full.

When might genuine semaglutide generics reach the UK market?

Patent expiry timelines are genuinely contested and vary by country. The core semaglutide compound patent in the US is the subject of ongoing litigation; European and UK filings follow their own schedules. Industry analysts have suggested a possible generic entry window in the early-to-mid 2030s for some markets, but predictions shift with court outcomes. Novo Nordisk's own pipeline includes next-generation molecules, which is a pattern typical of originator companies managing patent cliffs.

When generics do arrive in the UK, they will still be prescription-only medicines. Cost may fall significantly, which would be welcome news for patients, but the requirement for a clinical assessment before supply will remain. A prescriber will still need to confirm suitability, review your medical history and monitor for side effects. The timeline for semaglutide becoming generic in the UK is something our clinical team watches closely, including what it would mean for access and pricing. For current context on what Wegovy costs as a licensed private treatment, our Wegovy pricing page sets out the honest picture, including what a legitimate price should include.

What are the safe, licensed options for semaglutide-based weight management in the UK right now?

Two licensed semaglutide products exist for weight management in adults in the UK. Wegovy is the weekly injection, available from 0.25mg up to a maximum 7.2mg maintenance dose following MHRA approval of that strength in early 2026. As of June 2026, Wegovy is also available as a once-daily tablet (25mg maintenance dose), making it the first oral GLP-1 medicine licensed in the UK for weight management, a meaningful step for people who prefer not to inject. Ozempic contains the same molecule but is licensed for type 2 diabetes, not weight loss, and prescribing it for weight management would be off-label.

Eligibility for the licensed injection or tablet is based on BMI and weight-related health conditions, and lower BMI thresholds apply for some ethnic backgrounds under UK guidance. None of that replaces the individual clinical assessment: a prescriber weighs your full picture, not just the number on the BMI chart. If you'd like to explore your options, our weight-loss treatments overview covers both semaglutide and tirzepatide (Mounjaro) side by side, and the FAQs cover common eligibility questions. Both the injection and the tablet go in the fridge at home, though the tablet, once started, can sit on a shelf at room temperature, which makes it straightforward to slip into a morning routine before the kettle boils.

NICE's appraisal of semaglutide for weight management (TA875) sets out the clinical criteria under which it is recommended, which is useful background whether you are pursuing NHS or private treatment.